{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-seminomatous+Germ+Cell+Tumor&page=2",
    "query": {
      "condition": "Non-seminomatous Germ Cell Tumor",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-seminomatous+Germ+Cell+Tumor&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-26T00:05:29.206Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00070096",
      "title": "Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Extragonadal Germ Cell Tumor",
        "Ovarian Cancer",
        "Testicular Germ Cell Tumor"
      ],
      "interventions": [
        {
          "name": "ixabepilone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2003-08",
      "completion_date": "2007-06",
      "has_results": false,
      "last_update_posted_date": "2013-06-24",
      "last_synced_at": "2026-06-26T00:05:29.206Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00070096"
    },
    {
      "nct_id": "NCT04804007",
      "title": "Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Germ Cell Tumor",
        "Non-seminomatous Germ Cell Tumor",
        "Ovarian Germ Cell Tumor"
      ],
      "interventions": [
        {
          "name": "Etoposide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nabil Adra",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2021-03-03",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-06-26T00:05:29.206Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04804007"
    },
    {
      "nct_id": "NCT02034110",
      "title": "Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Dabrafenib",
          "type": "DRUG"
        },
        {
          "name": "Trametinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 206,
      "start_date": "2014-03-12",
      "completion_date": "2021-12-10",
      "has_results": true,
      "last_update_posted_date": "2023-08-21",
      "last_synced_at": "2026-06-26T00:05:29.206Z",
      "location_count": 8,
      "location_summary": "Little Rock, Arkansas • Santa Monica, California • Bethesda, Maryland + 4 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02034110"
    },
    {
      "nct_id": "NCT02499952",
      "title": "Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Germ Cell Neoplasms",
        "Testicular Neoplasms",
        "Non Seminomatous Germ Cell Tumors",
        "Mediastinal Neoplasms",
        "Genital Neoplasms, Male",
        "Genital Neoplasms, Female",
        "Ovarian Neoplasms"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nasser Hanna, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2016-01",
      "completion_date": "2017-01-13",
      "has_results": true,
      "last_update_posted_date": "2022-07-11",
      "last_synced_at": "2026-06-26T00:05:29.206Z",
      "location_count": 2,
      "location_summary": "Indianapolis, Indiana • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02499952"
    },
    {
      "nct_id": "NCT00104676",
      "title": "Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Extragonadal Germ Cell Tumor",
        "Teratoma",
        "Testicular Germ Cell Tumor"
      ],
      "interventions": [
        {
          "name": "bleomycin sulfate",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "UNICANCER",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "16 Years to 120 Years"
      },
      "enrollment_count": 263,
      "start_date": "2003-11-26",
      "completion_date": "2023-02-08",
      "has_results": true,
      "last_update_posted_date": "2025-02-06",
      "last_synced_at": "2026-06-26T00:05:29.206Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00104676"
    },
    {
      "nct_id": "NCT07218913",
      "title": "Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hearing Loss",
        "Metastatic Malignant Germ Cell Tumor",
        "Metastatic Malignant Nongerminomatous Germ Cell Tumor",
        "Metastatic Malignant Testicular Non-Seminomatous Germ Cell Tumor",
        "Metastatic Testicular Seminoma",
        "Stage II Testicular Cancer AJCC v8",
        "Stage III Testicular Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Audiometric Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Sodium Thiosulfate Anhydrous",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 44,
      "start_date": "2026-02-19",
      "completion_date": "2031-01-22",
      "has_results": false,
      "last_update_posted_date": "2026-04-17",
      "last_synced_at": "2026-06-26T00:05:29.206Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07218913"
    },
    {
      "nct_id": "NCT02689219",
      "title": "Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Germ Cell Tumors",
        "Testis Cancer",
        "Testicular Cancer",
        "Embryonal Carcinoma",
        "Nonseminomatous Germ Cell Tumor"
      ],
      "interventions": [
        {
          "name": "Brentuximab Vedotin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nabil Adra",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2016-03-09",
      "completion_date": "2019-01-23",
      "has_results": true,
      "last_update_posted_date": "2019-12-10",
      "last_synced_at": "2026-06-26T00:05:29.206Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Indianapolis, Indiana • New York, New York",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02689219"
    },
    {
      "nct_id": "NCT02834013",
      "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acinar Cell Carcinoma",
        "Adenoid Cystic Carcinoma",
        "Adrenal Cortical Carcinoma",
        "Adrenal Gland Pheochromocytoma",
        "Anal Canal Neuroendocrine Carcinoma",
        "Anal Canal Undifferentiated Carcinoma",
        "Angiosarcoma",
        "Apocrine Neoplasm",
        "Appendix Mucinous Adenocarcinoma",
        "Bartholin Gland Transitional Cell Carcinoma",
        "Basal Cell Carcinoma",
        "Bladder Adenocarcinoma",
        "Breast Metaplastic Carcinoma",
        "Cervical Adenocarcinoma",
        "Cholangiocarcinoma",
        "Chordoma",
        "Colorectal Squamous Cell Carcinoma",
        "Desmoid Fibromatosis",
        "Endometrial Transitional Cell Carcinoma",
        "Endometrioid Adenocarcinoma",
        "Esophageal Neuroendocrine Carcinoma",
        "Esophageal Undifferentiated Carcinoma",
        "Extrahepatic Bile Duct Carcinoma",
        "Extramammary Paget Disease",
        "Fallopian Tube Adenocarcinoma",
        "Fallopian Tube Transitional Cell Carcinoma",
        "Fibromyxoid Tumor",
        "Gallbladder Carcinoma",
        "Gastric Neuroendocrine Carcinoma",
        "Gastric Squamous Cell Carcinoma",
        "Gastric Undifferentiated Carcinoma",
        "Gastrointestinal Stromal Tumor",
        "Gestational Trophoblastic Tumor",
        "Giant Cell Carcinoma",
        "Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type",
        "Intestinal Neuroendocrine Carcinoma",
        "Intrahepatic Cholangiocarcinoma",
        "Lung Neuroendocrine Tumor",
        "Lung Sarcomatoid Carcinoma",
        "Major Salivary Gland Carcinoma",
        "Malignant Neoplasm of Unknown Primary",
        "Malignant Odontogenic Neoplasm",
        "Malignant Peripheral Nerve Sheath Tumor",
        "Malignant Solid Neoplasm",
        "Malignant Testicular Sex Cord-Stromal Tumor",
        "Metastatic Pituitary Neuroendocrine Tumor",
        "Minimally Invasive Lung Adenocarcinoma",
        "Mixed Mesodermal (Mullerian) Tumor",
        "Mucinous Adenocarcinoma",
        "Mucinous Cystadenocarcinoma",
        "Nasal Cavity Adenocarcinoma",
        "Nasal Cavity Carcinoma",
        "Nasopharyngeal Carcinoma",
        "Nasopharyngeal Low Grade Papillary Adenocarcinoma",
        "Nasopharyngeal Undifferentiated Carcinoma",
        "Oral Cavity Carcinoma",
        "Oropharyngeal Undifferentiated Carcinoma",
        "Ovarian Adenocarcinoma",
        "Ovarian Germ Cell Tumor",
        "Ovarian Mucinous Adenocarcinoma",
        "Ovarian Squamous Cell Carcinoma",
        "Ovarian Transitional Cell Carcinoma",
        "Pancreatic Acinar Cell Carcinoma",
        "Pancreatic Neuroendocrine Carcinoma",
        "Paraganglioma",
        "Paranasal Sinus Adenocarcinoma",
        "Paranasal Sinus Carcinoma",
        "Parathyroid Gland Carcinoma",
        "PEComa",
        "Penile Squamous Cell Carcinoma",
        "Peritoneal Mesothelial Neoplasm",
        "Placental Choriocarcinoma",
        "Primary Peritoneal High Grade Serous Adenocarcinoma",
        "Pseudomyxoma Peritonei",
        "Rare Disorder",
        "Scrotal Squamous Cell Carcinoma",
        "Seminal Vesicle Adenocarcinoma",
        "Seminoma",
        "Serous Cystadenocarcinoma",
        "Small Intestinal Adenocarcinoma",
        "Small Intestinal Squamous Cell Carcinoma",
        "Spindle Cell Neoplasm",
        "Teratoma With Somatic-Type Malignancy",
        "Testicular Non-Seminomatous Germ Cell Tumor",
        "Thyroid Gland Carcinoma",
        "Tracheal Carcinoma",
        "Transitional Cell Carcinoma",
        "Ureter Adenocarcinoma",
        "Ureter Squamous Cell Carcinoma",
        "Urethral Adenocarcinoma",
        "Urethral Squamous Cell Carcinoma",
        "Vaginal Adenocarcinoma",
        "Vaginal Squamous Cell Carcinoma, Not Otherwise Specified",
        "Vulvar Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 798,
      "start_date": "2017-01-30",
      "completion_date": "2027-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-06-26T00:05:29.206Z",
      "location_count": 1006,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 620 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02834013"
    },
    {
      "nct_id": "NCT00432094",
      "title": "Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Childhood Germ Cell Tumor",
        "Ovarian Cancer",
        "Teratoma"
      ],
      "interventions": [
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "thiotepa",
          "type": "DRUG"
        },
        {
          "name": "autologous hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "10 Years to 69 Years"
      },
      "enrollment_count": 23,
      "start_date": "2006-12-19",
      "completion_date": "2021-03",
      "has_results": true,
      "last_update_posted_date": "2022-05-17",
      "last_synced_at": "2026-06-26T00:05:29.206Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00432094"
    },
    {
      "nct_id": "NCT01808534",
      "title": "Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Central Nervous System Germ Cell Tumor",
        "Adult Teratoma",
        "Malignant Extragonadal Germ Cell Tumor",
        "Malignant Extragonadal Non-Seminomatous Germ Cell Tumor",
        "Extragonadal Seminoma",
        "Recurrent Malignant Testicular Germ Cell Tumor",
        "Recurrent Ovarian Germ Cell Tumor",
        "Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor",
        "Stage IV Extragonadal Seminoma",
        "Stage IV Ovarian Germ Cell Tumor"
      ],
      "interventions": [
        {
          "name": "palifosfamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2013-02",
      "completion_date": "2014-11",
      "has_results": true,
      "last_update_posted_date": "2015-07-02",
      "last_synced_at": "2026-06-26T00:05:29.206Z",
      "location_count": 3,
      "location_summary": "Indianapolis, Indiana • Philadelphia, Pennsylvania • Seattle, Washington",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01808534"
    }
  ]
}